406 related articles for article (PubMed ID: 16912295)
1. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
3. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
4. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
5. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
[TBL] [Abstract][Full Text] [Related]
7. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
[TBL] [Abstract][Full Text] [Related]
8. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
Jost S; Turelli P; Mangeat B; Protzer U; Trono D
J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3G & HTLV-1: inhibition without deamination.
Strebel K
Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
[TBL] [Abstract][Full Text] [Related]
11. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
12. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
13. Dancin' deaminase.
Harris RS; Matsuo H
Nat Struct Mol Biol; 2006 May; 13(5):380-1. PubMed ID: 16738602
[TBL] [Abstract][Full Text] [Related]
14. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
15. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
16. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins.
Huthoff H; Malim MH
Virology; 2005 Apr; 334(2):147-53. PubMed ID: 15780864
[TBL] [Abstract][Full Text] [Related]
17. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
Wang X; Dolan PT; Dang Y; Zheng YH
J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome.
Ebrahimi D; Anwar F; Davenport MP
Retrovirology; 2012 Dec; 9():113. PubMed ID: 23256516
[TBL] [Abstract][Full Text] [Related]
20. APOBEC-mediated editing of viral RNA.
Bishop KN; Holmes RK; Sheehy AM; Malim MH
Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
